Integrating Immunotherapy for NSCLC
By clicking the continue button above, I certify I have read the CME/CE information below.
Release Date: January 30, 2018
Expiration Date: January 30, 2019
The emergence of checkpoint inhibitors (CTLA4, PD1, PD-L1) has reawakened an interest in immunotherapy to treat various malignancies. New agents have rapidly been approved for use in melanoma, bladder cancer, renal cell, lung cancer, and other malignancies. These agents have a unique toxicity profile requiring careful clinical assessment, rapid intervention, and aggressive management of side effects.
This activity will provide a general overview of immunotherapy in cancer treatment, with a special focus on non-small cell lung cancer (NSCLC). Challenges of biomarker interpretation and use will also be addressed. Clinical data regarding 3 currently FDA-approved checkpoint inhibitors will be presented and discussed.
The primary audiences for this activity are:
- Community-based oncologists and hematologists; drivers of evidence-based practice changes, treatments, and care planning across multiple tumor types
- Oncology nurses, advanced practice nurse (APNs), registered nurses (RNs), and nurse practitioners (NPs); primary point persons for patient management and education
- Oncology, health-system, and managed-care pharmacists; responsible for dispensing cancer therapies, ensuring appropriate use, and including new agents on Formularies
- Oncology treatment-team members involved in managing patients with cancer and providing supportive services (e.g. financial advocates, nutrition plans, psychological assessment, genetic counseling, and navigation)
Gary I. Cohen, MD, FACP, FASCO
Associate Professor, Oncology
Johns Hopkins University
Director Emeritus, Berman Cancer Institute
Greater Baltimore Medical Center
Gary I. Cohen, MD is Director Emeritus of the Sandra and Malcolm Berman Cancer Institute at Greater Baltimore Medical Center (GBMC). He completed his undergraduate training at Duke University and graduated medical school at the University of Maryland. He subsequently completed his fellowship training in medical oncology at the Dana Farber Cancer Institute of Harvard University. He remained on the staff at Harvard to pursue his research interest in bone marrow cell growth. During that time he also completed a fellowship in hematology. He currently holds an appointment as Associate Professor in the Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and is board-certified in internal medicine, medical oncology, and hematology. He is a Fellow of the American Society of Clinical Oncology and Fellow of the American College of Physicians.
Dr. Cohen established the Cancer Center at GBMC after being appointed Director in 1990. The center has been listed by US News and World Report as one of the top 50 cancer programs in the US. He has co-authored numerous articles in the medical literature on various aspects of clinical cancer research. Dr. Cohen has been an active participant in the ECOG-ACRIN national cooperative clinical trials group, chairs the Community Scientific Committee, serves as Community Co-chair of the Melanoma Committee, and sits on the ECOG-ACRIN Executive Council. He is a Founder and Board Member of Gilchrist Hospice Care in Baltimore.
At the conclusion of this session, participants should be able to demonstrate the ability to:
- Incorporate treatment pathways and quality measures to ensure patients with advanced non-small cell lung cancer (NSCLC) receive guideline-consistent care
- Evaluate the sequential and combination administration of immune checkpoint inhibitors to optimize survival in patients with NSCLC
- Discuss current recommendations for diagnostic testing to facilitate treatment selection of patients with NSCLC
- Assess the safety and efficacy of currently approved and emerging agents for primary and subsequent management of advanced NSCLC with attention to cost/benefit and toxicity considerations
- Evaluate communication strategies and resources to increase patient access and engagement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit TM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.
Total number of CE credits made available at this conference is 1.00 hours (0.1 CEUs).
A statement of credit will be issued only upon receipt of a completed activity evaluation.
This is an application-based activity.
For questions regarding CME/CE credit, the post-test, evaluation, please email firstname.lastname@example.org.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Potomac Center for Medical Education, and Rockpointe Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.1 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Gary I. Cohen, MD, FACP, FASCO: Speaker's Bureau: Genzyme, NantHealth; Shareholder: Celgene
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Shawna Graves, PhD; Blair St. Amand; Judi Smelker-Mitchek, RN, MSN, MBA; Trace Hutchinson, PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, MSN, FACEHP, RN, CHCP; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
Alex Ganetsky, PharmD: Honoraria/Advisory Board: Jazz; Speaker’s Bureau: Amgen, Incyte
The content of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
Instructions for Participants and Obtaining CME/CE Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/CE activity in its entirety, and then complete the post-test, with a score of 66% or better, and evaluation. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Jointly provided by Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.